ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Corporate One, 84 Hotham Street, Preston, VIC 3072 Australia Telephone: + 61 3 9863 6472 investor@arovella.com | www.arovella.com ASX Release 9 September 2026 Dear Shareholder ANNUAL GENERAL MEETING (2026 AGM) Notice is hereby given...
Notification of 2026 AGM Date
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Clinical manufacturing batch released, first site activated
- Corporate Governance Statement
- Appendix 4G
- Appendix 4E and Annual Report
- Notification regarding unquoted securities - ALA
Later from Arovella Therapeutics
- 2026 ESG Report
- The path to first patient dosing
- Notice of Annual General Meeting/Proxy Form
- Cell and Gene Innovation Spotlight Presentation
- Second Clinical Batch Released for Immediate Patient Use
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics